Monthly Archives: February 2020

Ternium SA to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 19, 2020 / Ternium SA (NYSE:TX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 19, 2020 at 8:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/58716

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 576886

Empower Clinics Launches Improved Line of CBD Products and Confirms 2020 Hemp Handlers Licence for Extraction Facility in Oregon

Empowers' CBD product line Sollievo has been reformulated to include 900mg of CBD

VANCOUVER BC / ACCESSWIRE / February 19, 2020 / EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) ("Empower" or the "Company"), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce it has launched a series of re-formulated versions of it's CBD tincture product line SOLLIEVO. Italian for Relief.

The new formulated Sollievo is non-GMO, non-psychoactive, has rapid bioavailability and is sourced from USA grown hemp. The products are all third-party lab tested for quality, and the new terpene profiles for each of the four tincture categories of Chronic Pain, Digestion, Insomnia and Anxiety, are aimed to promote mind and body wellness.

"We have spent the last few months dramatically increasing the potency, flavour profiles, and profitability of the Sollievo tincture product lines", said Dustin Klein, SVP Business Development and Director, Empower Clinics Inc. "Our new formulations were manufactured in a state-of-the-art CGMP facility, ensuring quality and consistency, and by tripling the amount of CBD per unit to 900mg, it provides a more potent single dose to our customers, to our patients."

The new Sollievo tincture lines are now available in the Sun Valley Health wellness clinics, are available online and will be a standard product offering in the Sun Valley Health franchise locations.

The Company also announces it has been awarded its 2020 Oregon Department of Agriculture hemp handlers license, ensuring that the new Sandy, OR extraction and production facility is compliant and licensed to operate under the regulatory framework of the State.

"I'm excited to have our new Sollievo tinctures available for purchase, and so proud of Dustin and our team who have brought an exemplary product to market." said Steven McAuley, Chairman & CEO of Empower. "Having the hemp handlers license in place for 2020 and continuing toward the close of our Heritage Cannabis joint venture, allows us to control our supply chain and to bring best-in-class CBD products to domestic and international markets."

The Company also advises that Mat Lee's position as CFO has concluded and we thank Mat for his contributions. The Company continues to be supported by Invictus Accounting and its team of specialists, who have been integral to creating financial and accounting controls that allow us to report quarterly results well in advance of requirements. The Company has commenced a search for a new Chief Financial Officer.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it's first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
s.mcauley@empowerclinics.com
604-789-2146

Investors: Dustin Klein
SVP, Business Development
dustin@svmmjcc.com
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: rs@maricom.ca, T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding; the Company's intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower's patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company's patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

ReleaseID: 576957

Verisk Analytics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 19, 2020 / Verisk Analytics, Inc. (NASDAQ:VRSK) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 19, 2020 at 8:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/58301

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 576909

Accounts Payable Automation & Approval App Works with Quickbooks Online

Centsoft Accounts Payable Automation and Approval Workflow Cloud Software integrates with Quickbooks Online with just a few clicks. Business owners appreciate the ease of integration.

Chicago, United States – February 19, 2020 /PressCable/

Centsoft has announced that their AP Automation cloud software with mobile approval workflows integrates with Quickbooks Online very quickly – with just a few clicks.

Quickbooks Online is one of the world’s leading accounting packages for small and medium sized businesses. Having a seamless integration experience is important for companies that do not have the time or money to deal with complex integration procedures.

Centsoft has a fully transparent integration with QuickBooks Online. All the accounts payable work with supplier invoices is done within Centsoft. In addition to the invoices being posted to the correct account, project and cost center, users can also see the invoice image in both Centsoft and QuickBooks.

“Centsoft integrates with Quickbooks and everything you do in Centsoft is seamlessly updated,” said Michael Cichy, Centsoft, “Centsoft automatically records important settings including the vendor register, vendor accounts, and currency. We find that customers love the integration experience they have with Centsoft and Quickbooks Online. No one needs more complexity added to their workday.”

Centsoft has built-in invoice scanning software. Quickbooks users scan paper invoices directly into Centsoft, or send electronic PDF invoices directly to the intuitive Centsoft dashboard. Invoice data is captured and the data is recorded in Centsoft. That means manual data entry is reduced and there is time for more valuable tasks.

Centsoft users create dynamic approval workflows and submit vendor invoices for approval to one or several people at once, allowing anyone on the team to approve invoices on any device 24/7.

AI software proactively suggests the best way to record and process invoices for fast and easy approval, or if an adjustment is required. The powerful search engine allows for easy access to historical data and a wide range of insightful reports.

For more information about Centsoft and the Quickbooks Online Integration, visit https://centsoftautomation.com/how-it-works/

About Centsoft

Centsoft, a subsidiary of Palette Software, offers robust and cloud-based software to streamline all of the steps in the accounts payable process. Centsoft’s AI learns and proactively suggests the best way to record and process invoices for fast and easy approval. Centsoft is a leading provider of SaaS solutions that automates the management of incoming invoices for over 3,000 companies. Centsoft easily integrates with Quickbooks Desktop and Quickbooks Online.

https://centsoftautomation.com

# # #

For more information regarding Centsoft contact:

Michael Cichy

Centsoft

Phone: 508-341-8101

Email: michael.cichy@palettesoftware.com

Contact Info:
Name: Michael Cichy
Email: Send Email
Organization: Centsoft
Address: 330 North Wabash Ave. 23rd Floor, Chicago, Illinois 60611, United States
Phone: +1-508-341-8101
Website: https://centsoftautomation.com

Source: PressCable

Release ID: 88947192

Venture Vanadium Inc. Provides Overview of Mineral-Rich Desgrobois Vanadium Project, Recent Work & Upcoming 3-Phase Exploration Program

PITTSBURGH, PA / ACCESSWIRE / February 19, 2020 / Venture Vanadium Inc. ("Venture Vanadium" or "the Company") (OTC:VENV), a progressive American battery metals exploration and development company, is pleased to provide an overview of the Company's Desgrobois Vanadium Project, including work completed on the property in 2019 and details of the planned 3-phase exploration program to provide a clearer understanding of the project's underlying geologic structure.

"We're excited to have secured the Desgrobois Vanadium Project at a time when demand for secure, domestic supplies of vanadium continues to grow," said Venture Vanadium's President and CEO, Ian Ilsley. "Our property includes 2 past-producing open-pit iron-titanium mines, and the NI 43-101 report from 2009 / 2019 contains valuable insights into past exploration efforts and the geological data available on the Desgrobois Vanadium Project property and immediately adjacent claims. Our next steps are to build on our activities from 2019 to better define the project's mineralization."

For more information about the Desgrobois Vanadium Project, including photos of recent activity, visit https://venturevanadium.com/project/.

Note: While potential exploration zones and targets have been identified, no reserves or resources have been officially established at this time for the Desgrobois Vanadium Project since a Qualified Person has not done sufficient work on the mineralization to determine an accurate grade or tonnage.

PROJECT OVERVIEW

We hold a 100% interest in the Desgrobois Vanadium Project, which comprises 30 contiguous claims totaling 4,422 acres (~1,789 hectares) within the mineral-rich Canadian Grenville Structural Province, roughly 75 miles (~120 km) north of the US border, near the eastern coast of Quebec, Canada.

The project represents potential for the recovery of titanium, iron and vanadium from two zones. In 2009, prior to Venture Vanadium acquiring the Project property, an NI 43-101 report was completed on most of the claims currently held by Venture Vanadium as well as on some claims that Venture Vanadium does not hold due to their undesirable potential for production.

DEPOSIT TYPE: VTM

The Desgrobois Vanadium Project represents what is known as a VTM deposit (vanadiferous titanomagnetite). From 80 to 85% of the world's supply of vanadium is derived from VTM deposits, either directly from mined ore or from steelmaking slags produced by processing the ores.

BRIEF OVERVIEW OF THE PROJECT REGION

Our claims are located in the mining-friendly, mineral-rich province of Quebec. Access to the Project is via Highways 15 and 117, then paved and gravel roads that cross the property site. The nearest major town is Sainte-Agathe-des-Monts, approximately 3 miles (~5 km) to the southeast.

Electric power, railway, airport and highways are only a few miles from the property. Water supply is available in large quantities from several lakes located within the property boundary. The Canadian Pacific Railway crosses the northeast portion of the property.

For a full understanding of all the advantages the region represents, please visit our Region page: https://venturevanadium.com/region/

PAST EXPLORATION & SUPPORTING GEOLOGIC DATA

The Desgrobois Vanadium Project property is located within the Canadian Grenville Structural Province, where numerous deposits of titaniferous magnetite, magnetite-ilmenite-apatite and massive ferroanilmenite have been known since the 1850s.

According to the NI 43-101 report from 2009 (updated 2019), aeromagnetic and ground-based gravimetric surveys conducted in 2007-2008 indicate important undiscovered iron-titanium mineral reserve in the vicinity of the 2 past-producing open-pit iron-titanium mines on our property: the Ivry and Desgrobois mines.

The results obtained from both surveys suggest that wherever positive or negative magnetic anomalies were found, they are associated with existing rock bodies containing massive or disseminated iron-titanium mineralization, as confirmed by the gravimetric survey.

The helicopter-borne magnetic survey revealed strong magnetic highs concentrated around the old Desgrobois-Ivry deposits and to the southwest. Strong magnetic lows, meanwhile, also appear in the vicinity of the old Ivry and Desgrobois pits. In addition, a gravimetric study in the vicinity of the Ivry pit produced at least 3 anomalous areas in the Bouguer and Residual Gravity maps that correspond to excess mass at shallow depth.

As such, these regions constitute targets for further exploration and are interpreted as an indication of iron-titanium oxide bodies at depth.

FIRST TARGET ZONE: THE DESGROBOIS DEPOSIT

The Desgrobois target anomaly forms an irregular titaniferous magnetite mass and is substantially larger than the known Ivry deposit to the immediate south on our property. In 1953, a total of 22 diamond drill holes totaling 3,713 feet (~1,132 m) were drilled on the Desgrobois target on a portion of one of the deposit's two anomalies. One diamond drill hole in the second anomaly showed 40 feet (~12 m) of massive mineralization.

From previous exploration work, prior to 2009, the Desgrosbois Zone represents two zones:

a higher-grade exploration target of between 5-6 million tons, grading between 40-42% iron, 10-12% titanium dioxide, and between 0.12-0.15% vanadium, and,
a disseminated exploration target of between 900,000 and 1.1 million tons, grading between 25-26% iron, and between 6-7 % titanium dioxide, and between 0.1-0.15% vanadium.

SECOND TARGET ZONE: THE TITANIUM DEVELOPMENT ZONE

The Titanium Development Zone is located in the south-central area of our property, roughly 1.5 miles (~2.5 km) south of the Desgrobois deposit. The Titanium Development Zone, from previous exploration, represents an exploration target of between 2,500,000 and 3,000,000 tons grading between 37-39% iron, 29-31% titanium dioxide, and between 0.1 and 0.2 % vanadium. The previous work indicates that there may be a central zone amenable to removal by open pit methods.

ADDITIONAL POTENTIAL TARGETS

Two large negative magnetic anomalies lie on the western extension of our claim block, representing additional potential targets to explore. As well, the Ivry deposit , located immediately south of the Titanium Development Zone target contains an exploration target as indicated from previous drilling to have an exploration potential of between 2.5 -3 million tons grading between 29-31% titanium and 37-39% iron, with a vanadium content of undetermined level.

ONGOING ANALYSIS & 2019 ACTIVITY

Our team is actively extending the Company's knowledge of the Desgrobois Vanadium Project's geologic profile to determine the potential for production of vanadium, iron and titanium.

Most recently, that activity included our work program in August 2019. Stewart A. Jackson, PhD. P.Geo., Consultant Geologist and Jocelyn Pelletier, P.Geo., Consultant Geologist visited the 2 past-producing open-pit iron-titanium mines on our property: the Ivry Mine and the Desgrosbois Mine.

Extensive surface samples were taken at both sites, which included examples of massive mineralization. Results from this activity can be found via an independent report located on our website.

In September, Ian Ilsley, President & CEO was joined by Jocelyn Pelletier, P.Geo., during a follow-up visit to both the Ivry Mine and the Desgrosbois Mine on our Desgrobois Vanadium Project.

3-PHASE EXPLORATION WORK PROGRAM PLANS

To provide a clearer understanding of the underlying geologic structure, we plan for a 3-phase exploration program that will include a comprehensive diamond drill hole campaign on 5 priority targets within the Desgrobois Zone and the Titanium Development Zone. These targets will be defined by data from the airborne magnetic surveys. Additionally, reconnaissance drilling on the large negative magnetic anomalies on the western extension is recommended.

A high-level overview of the planned 3-phase exploration program is outlined below.

Phase I:

Compilation and evaluation of previous of geological, geochemical and geophysical surveys
Geological study to determine the extent and the grade of titanium-iron-vanadium mineralization

Phase II:

Diamond drill hole campaign with a target depth of ~330 feet (~100 metres)
8 holes within the Desgrobois Zone and the Titanium Development Zone
2 holes on the western extension negative magnetic anomalies

Phase III:

Additional drilling and bulk sampling the main target areas to confirm previous results and outline the full extent of the titanium-iron-vanadium mineralization
Positive results on initial drilling of the 2 western anomalies would be followed by additional drilling to confirm previous results and to outline the full extent of the mineralization
Metallurgical test work would establish the best process for separating the titanium, iron and vanadium
A preliminary assessment of feasibility would be prepared with emphasis on the economics of the project

For more information about the Desgrobois Vanadium Project, including its exploration zones and targets, surrounding region, and photos of recent activity, visit https://venturevanadium.com/project/.

On behalf of the Board,

Ian Ilsley
President and Chief Executive Officer

About Venture Vanadium Inc.

Venture Vanadium (OTC:VENV) is a progressive American battery metals exploration and development company. Our focus is finding, developing and producing resources to help meet growing market demand for battery metals. Our Desgrobois Vanadium Project, roughly 75 miles (~120 km) north of the US border, near the eastern coast of Quebec, Canada, represents potential for the recovery of titanium, iron and vanadium from two zones. We hold a 100% interest in 30 contiguous claims totaling 4,422 acres (~1,789 hectares) within the mineral-rich Canadian Grenville Structural Province. In 2009, prior to Venture Vanadium acquiring the Project property, an NI 43-101 report was completed on most of the claims currently held by Venture Vanadium as well as on some claims that Venture Vanadium does not hold due to their undesirable potential for production.. For more information visit our website at www.venturevanadium.com.

Contact:
Venture Vanadium Inc.
One Oxford Centre, 301 Grant Street, Suite 4300
Pittsburgh, PA 15219
Tel: 1.412.577.2499
Fax: 1.412.255.3701
www.venturevanadium.com

Forward-Looking Statements:

Certain statements in this release are forward-looking statements. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as "may", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, and other factors, many of which are beyond the control of Venture Vanadium Inc. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Undue reliance should not be placed on the forward-looking information because Venture Vanadium Inc. can give no assurance that they will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, Venture Vanadium Inc. disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, Venture Vanadium Inc. undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

SOURCE: Venture Vanadium Inc.

ReleaseID: 576959

Bausch Health Cos., Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 19, 2020 / Bausch Health Cos., Inc. (TSX:BHC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 19, 2020 at 8:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/58300

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 576876

Medexus Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 19, 2020 / Medexus Pharmaceuticals, Inc. (OTCMKTS:PDDPF) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on February 19, 2020 at 8:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/59412

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 576884

NHI Announces Fourth Quarter 2019 Results

MURFREESBORO, TN / ACCESSWIRE / February 19, 2020 / National Health Investors, Inc. (NYSE:NHI) announced today its net income attributable to common stockholders, its Funds From Operations ("FFO"), its Normalized Funds From Operations and its Normalized Adjusted Funds From Operations ("AFFO") for the three months and year ended December 31, 2019.

2019 Highlights

GAAP net income attributable to common stockholders of $.95 for the fourth quarter, $3.67 year-to-date, per diluted common share
AFFO of $1.30 for the fourth quarter and $5.10 year-to-date, per diluted common share
Announced or completed $329 million in real estate and mortgage note investments year-to-date
Ample liquidity with $250 million available to draw on revolving credit facility
Maintained low leverage balance sheet at 4.7x net debt-to-annualized adjusted EBITDA
Q4 2019 fixed charge coverage remains conservative at 5.7x
Portfolio lease coverage remains strong at 1.66x
Transitioned three non-compliant leases to high-quality operating partners

2020 Guidance

The Company currently expects net income to be in the range of $4.33 to $4.47 per diluted common share, Normalized FFO for 2020 to be in the range of $5.67 to $5.71 per diluted common share and Normalized AFFO to be in the range of $5.31 to $5.35 per diluted common share. The Company's guidance range for the full year 2020, with underlying assumptions and timing of certain transactions, is set forth and reconciled below:

 

 
Full-Year 2020 Range
 

 

 
Low
 
 
High
 

Net income attributable to common stockholders – diluted

 
$
4.33
 
 
$
4.47
 

Plus: depreciation1

 
 
1.81
 
 
 
1.86
 

Plus: gain on disposal of real estate

 
 
(.47
)
 
 
(.62
)

Normalized FFO per diluted common share

 
$
5.67
 
 
$
5.71
 

Less: straight-line rental income1

 
 
(0.46
)
 
 
(0.48
)

Plus: other unconsolidated subsidiary adjustments2

 
 
0.06
 
 
 
0.08
 

Plus: amortization of debt issuance costs and original issue discounts

 
 
0.03
 
 
 
0.04
 

Plus: amortization of lease incentives

 
 
0.02
 
 
 
0.02
 

Less: amortization of nonrefundable entrance fees2

 
 
(0.01
)
 
 
(0.02
)

Normalized AFFO per diluted common share

 
$
5.31
 
 
$
5.35
 

FAD items (in thousands)

 
Low
 
 
High
 

Non-cash stock compensation

 
$
3,400
 
 
$
3,600
 

Non-refundable entrance fees2

 
$
650
 
 
$
820
 

Routine capital expenditures2

 
$
420
 
 
$
420
 

 
 
 
 
 
 
 
 
 

1 net of amounts related to non-controlling interests

2 reflects NHI share of unconsolidated Timber Ridge OpCo subsidiary

The Company's guidance range reflects the existence of volatile economic conditions. The Company's guidance range is based on a number of assumptions, many of which are outside the Company's control and all of which are subject to change. The Company's guidance range allows for the uncertainty inherent in the structure and timing of the financing required to fund previously announced investments and any pending new investments. The Company's guidance may change if actual results vary from these assumptions.

Financial Results

Net income attributable to common stockholders per diluted common share for the three months ended December 31, 2019 was $.95, an increase of 9.2% from the same period in the prior year. Net income attributable to common stockholders per diluted common share for the year ended December 31, 2019 was $3.67, unchanged from the same period in the prior year. Net income for the year ended December 31, 2019 includes a write-down of $2,500,000 on two assisted living properties which we have classified as held for sale.
Normalized FFO per diluted common share for the three months ended December 31, 2019 was $1.41, an increase of 4.4% from the same period in the prior year. Normalized FFO per diluted common share for the year ended December 31, 2019 was $5.50, an increase of 0.7% from the same period in the prior year.
Normalized AFFO per diluted common share for the three months ended December 31, 2019 was $1.30, an increase of 2.4% over the same period in the prior year. Normalized AFFO per diluted common share for the year ended December 31, 2019 was $5.10, an increase of 1.2% over the same period in the prior year.
NAREIT FFO per diluted common share for the three months ended December 31, 2019 was $1.39, an increase of 6.9% from the same period in the prior year. NAREIT FFO per diluted common share for the twelve months ended December 31, 2019 was $5.49, an increase of 2.4% over the same period in the prior year.
Net income, Normalized FFO, Normalized AFFO and NAREIT FFO per common share for the year ended December 31, 2019 includes the dilutive impact of 1,887,075 common shares issued since December 31, 2018.

FFO, as defined by the National Association of Real Estate Investment Trusts ("NAREIT") and applied by us, is net income (computed in accordance with GAAP), excluding gains (or losses) from sales of real estate property, plus real estate depreciation and amortization, and after adjustments for unconsolidated partnerships and joint ventures, if any. The Company defines Normalized FFO as FFO adjusted for certain items which may create some difficulty in comparing FFO for the current period to similar prior periods. We define Normalized AFFO as Normalized FFO excluding the effects of straight-line lease revenue, amortization of debt issuance costs and the non-cash amortization of the original issue discount of our unsecured convertible notes. These supplemental non-GAAP performance measures may not be comparable to similarly titled measures used by other REITs.

The reconciliation of net income attributable to common stockholders to our FFO, Normalized FFO, Normalized AFFO and Normalized Funds Available for Distribution ("FAD") is included as a table to this press release and filed in the Company's Form 10-K with the Securities and Exchange Commission.

Investor Conference Call and Webcast

NHI will host a conference call on Wednesday, February 19, 2020, at 12 p.m. ET, to discuss fourth quarter results. The number to call for this interactive teleconference is (800) 582-1443, with the confirmation number 21950888. The live broadcast of NHI's fourth quarter conference call will be available online at www.nhireit.com. The online replay will follow shortly after the call and continue for approximately 90 days.

About National Health Investors

Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals. Visit www.nhireit.com for more information.

Reconciliation of FFO, Normalized FFO, Normalized AFFO and Normalized FAD
(in thousands, except share and per share amounts)

 

 
Three Months Ended
 
 
Year Ended
 

 

 
December 31,
 
 
December 31,
 

 

 
2019
 
 
2018
 
 
2019
 
 
2018
 

Net income attributable to common stockholders

 
$
42,039
 
 
$
37,083
 
 
$
160,456
 
 
$
154,333
 

Elimination of certain non-cash items in net income:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Depreciation

 
 
19,610
 
 
 
18,068
 
 
 
76,816
 
 
 
71,349
 

Depreciation related to noncontrolling interest

 
 
(22
)
 
 

 
 
 
(52
)
 
 

 

Impairment of real estate

 
 

 
 
 

 
 
 
2,500
 
 
 

 

NAREIT FFO attributable to common stockholders

 
 
61,627
 
 
 
55,151
 
 
 
239,720
 
 
 
225,682
 

Loss on convertible note retirement

 
 
823
 
 
 

 
 
 
823
 
 
 
738
 

Non-cash write-off of straight-line rent receivable

 
 

 
 
 
2,265
 
 
 

 
 
 
3,701
 

Note receivable impairment

 
 

 
 
 
(50
)
 
 

 
 
 
363
 

Recognition of unamortized note receivable commitment fees

 
 

 
 
 

 
 
 

 
 
 
(515
)

Normalized FFO attributable to common stockholders

 
 
62,450
 
 
 
57,366
 
 
 
240,543
 
 
 
229,969
 

Straight-line lease revenue, net

 
 
(5,830
)
 
 
(4,220
)
 
 
(22,084
)
 
 
(21,736
)

Straight-line lease revenue, net, related to noncontrolling interest

 
 
6
 
 
 

 
 
 
13
 
 
 

 

Amortization of lease incentives

 
 
238
 
 
 
147
 
 
 
845
 
 
 
387
 

Amortization of original issue discount

 
 
176
 
 
 
191
 
 
 
761
 
 
 
788
 

Amortization of debt issuance costs

 
 
693
 
 
 
698
 
 
 
2,805
 
 
 
2,526
 

Normalized AFFO attributable to common stockholders

 
 
57,733
 
 
 
54,182
 
 
 
222,883
 
 
 
211,934
 

Non-cash share-based compensation

 
 
691
 
 
 
359
 
 
 
3,646
 
 
 
2,490
 

Normalized FAD attributable to common stockholders

 
$
58,424
 
 
$
54,541
 
 
$
226,529
 
 
$
214,424
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

BASIC

 
 
 
 
 
 
 
 
 
 
 
 

Weighted average common shares outstanding

 
 
44,107,770
 
 
 
42,351,443
 
 
 
43,417,828
 
 
 
41,943,873
 

NAREIT FFO attributable to common stockholders per share

 
$
1.40
 
 
$
1.30
 
 
$
5.52
 
 
$
5.38
 

Normalized FFO attributable to common stockholders per share

 
$
1.42
 
 
$
1.35
 
 
$
5.54
 
 
$
5.48
 

Normalized AFFO attributable to common stockholders per share

 
$
1.31
 
 
$
1.28
 
 
$
5.13
 
 
$
5.05
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

DILUTED

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Weighted average common shares outstanding

 
 
44,328,847
 
 
 
42,568,720
 
 
 
43,703,248
 
 
 
42,091,731
 

NAREIT FFO attributable to common stockholders per share

 
$
1.39
 
 
$
1.30
 
 
$
5.49
 
 
$
5.36
 

Normalized FFO attributable to common stockholders per share

 
$
1.41
 
 
$
1.35
 
 
$
5.50
 
 
$
5.46
 

Normalized AFFO attributable to common stockholders per share

 
$
1.30
 
 
$
1.27
 
 
$
5.10
 
 
$
5.04
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

See Notes to Reconciliation of FFO, Normalized FFO, Normalized AFFO and Normalized FAD.

Notes to Reconciliation of FFO, Normalized FFO, Normalized AFFO and Normalized FAD

These supplemental operating performance measures may not be comparable to similarly titled measures used by other REITs. Consequently, our Funds From Operations ("FFO"), Normalized FFO, Normalized Adjusted Funds From Operations ("AFFO") and Normalized Funds Available for Distribution ("FAD") may not provide a meaningful measure of our performance as compared to that of other REITs. Since other REITs may not use our definition of these operating performance measures, caution should be exercised when comparing our Company's FFO, Normalized FFO, Normalized AFFO and Normalized FAD to that of other REITs. These financial performance measures do not represent cash generated from operating activities in accordance with generally accepted accounting principles ("GAAP") (these measures do not include changes in operating assets and liabilities) and therefore should not be considered an alternative to net earnings as an indication of operating performance, or to net cash flow from operating activities as determined by GAAP as a measure of liquidity, and are not necessarily indicative of cash available to fund cash needs.

Funds From Operations – FFO

FFO, as defined by the National Association of Real Estate Investment Trusts ("NAREIT") and applied by us, is net income (computed in accordance with GAAP), excluding gains (or losses) from sales of real estate property, plus real estate depreciation and amortization, and after adjustments for unconsolidated partnerships and joint ventures, if any. The Company's computation of FFO may not be comparable to FFO reported by other REITs that do not define the term in accordance with the current NAREIT definition or have a different interpretation of the current NAREIT definition from that of the Company; therefore, caution should be exercised when comparing our Company's FFO to that of other REITs. Diluted FFO assumes the exercise of stock options and other potentially dilutive securities. Normalized FFO excludes from FFO certain items which, due to their infrequent or unpredictable nature, may create some difficulty in comparing FFO for the current period to similar prior periods, and may include, but are not limited to, impairment of non-real estate assets, gains and losses attributable to the acquisition and disposition of assets and liabilities, and recoveries of previous write-downs.

We believe that FFO and normalized FFO are important supplemental measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that uses historical cost accounting for depreciation could be less informative, and should be supplemented with a measure such as FFO. The term FFO was designed by the REIT industry to address this issue.

Adjusted Funds From Operations – AFFO

In addition to the adjustments included in the calculation of normalized FFO, normalized AFFO excludes the impact of any straight-line lease revenue, amortization of the original issue discount on our convertible senior notes and amortization of debt issuance costs.

We believe that normalized AFFO is an important supplemental measure of operating performance for a REIT. GAAP requires a lessor to recognize contractual lease payments into income on a straight-line basis over the expected term of the lease. This straight-line adjustment has the effect of reporting lease income that is significantly more or less than the contractual cash flows received pursuant to the terms of the lease agreement. GAAP also requires the original issue discount of our convertible senior notes and debt issuance costs to be amortized as non-cash adjustments to earnings. Normalized AFFO is useful to our investors as it reflects the growth inherent in the contractual lease payments of our real estate portfolio.

Funds Available for Distribution – FAD

In addition to the adjustments included in the calculation of normalized AFFO, normalized FAD excludes the impact of non-cash stock based compensation.

We believe that normalized FAD is an important supplemental measure of operating performance for a REIT as a useful indicator of the ability to distribute dividends to shareholders. Additionally, normalized FAD improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods and (iii) results among REITs, more meaningful. Because FAD may function as a liquidity measure, we do not present FAD on a per-share basis.

Condensed Statements of Income
(in thousands, except share and per share amounts)

 

 
Three Months Ended
 
 
Twelve Months Ended
 

 

 
December 31,
 
 
December 31,
 

 

 
2019
 
 
2018
 
 
2019
 
 
2018
 

 

 
(unaudited)
 
 
(unaudited)
 

Revenues:

 
 
 
 
 
 
 
 
 
 
 
 

Rental income

 
$
75,404
 
 
$
70,004
 
 
$
294,182
 
 
$
280,813
 

Interest income and other

 
 
6,790
 
 
 
3,991
 
 
 
23,899
 
 
 
13,799
 

 

 
 
82,194
 
 
 
73,995
 
 
 
318,081
 
 
 
294,612
 

Expenses:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Depreciation

 
 
19,610
 
 
 
18,068
 
 
 
76,816
 
 
 
71,349
 

Interest

 
 
14,374
 
 
 
12,847
 
 
 
56,299
 
 
 
49,055
 

Legal

 
 
98
 
 
 
(396
)
 
 
507
 
 
 
309
 

Franchise, excise and other taxes

 
 
109
 
 
 
309
 
 
 
1,550
 
 
 
1,166
 

General and administrative

 
 
3,611
 
 
 
2,818
 
 
 
13,399
 
 
 
12,547
 

Property taxes and insurance on leased properties

 
 
1,593
 
 
 

 
 
 
5,798
 
 
 

 

Loan and realty losses

 
 
(60
)
 
 
3,266
 
 
 
2,440
 
 
 
5,115
 

 

 
 
39,335
 
 
 
36,912
 
 
 
156,809
 
 
 
139,541
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Income before loss on convertible note retirement

 
 
42,859
 
 
 
37,083
 
 
 
161,272
 
 
 
155,071
 

Loss on convertible note retirement

 
 
(823
)
 
 

 
 
 
(823
)
 
 
(738
)

Net income

 
$
42,036
 
 
$
37,083
 
 
$
160,449
 
 
$
154,333
 

Less: net loss attributable to noncontrolling interest

 
 
3
 
 
 

 
 
 
7
 
 
 

 

Net income attributable to common stockholders

 
$
42,039
 
 
$
37,083
 
 
$
160,456
 
 
$
154,333
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Weighted average common shares outstanding:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic

 
 
44,107,770
 
 
 
42,351,443
 
 
 
43,417,828
 
 
 
41,943,873
 

Diluted

 
 
44,328,847
 
 
 
42,568,720
 
 
 
43,703,248
 
 
 
42,091,731
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Earnings per common share:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net income attributable to common stockholders – basic

 
$
.95
 
 
$
.88
 
 
$
3.70
 
 
$
3.68
 

Net income attributable to common stockholders – diluted

 
$
.95
 
 
$
.87
 
 
$
3.67
 
 
$
3.67
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Selected Balance Sheet Data
(in thousands)

 

 
December 31, 2019
 
 
December 31, 2018
 

 

 
 
 
 
 
 

Real estate properties, net

 

2,560,393
 
 

2,366,882
 

Mortgage and other notes receivable, net

 

340,143
 
 

246,111
 

Cash and cash equivalents

 

5,215
 
 

4,659
 

Straight-line rent receivable

 

86,044
 
 

105,620
 

Assets held for sale, net

 

18,420
 
 


 

Other assets

 

32,020
 
 

27,298
 

Debt

 

1,440,465
 
 

1,281,675
 

National Health Investors Stockholders' Equity

 

1,497,631
 
 

1,389,713
 

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding the Company's, tenants', operators', borrowers' or managers' expected future financial position, results of operations, cash flows, funds from operations, dividend and dividend plans, financing opportunities and plans, capital market transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, acquisition integration, growth opportunities, expected lease income, continued qualification as a real estate investment trust ("REIT"), plans and objectives of management for future operations, continued performance improvements, ability to service and refinance our debt obligations, ability to finance growth opportunities, and similar statements including, without limitation, those containing words such as "may", "will", "believes", "anticipates", "expects", "intends", "estimates", "plans", and other similar expressions are forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Such risks and uncertainties include, among other things; the operating success of our tenants and borrowers for collection of our lease and interest income; the success of property development and construction activities, which may fail to achieve the operating results we expect; the risk that our tenants and borrowers may become subject to bankruptcy or insolvency proceedings; risks related to governmental regulations and payors, principally Medicare and Medicaid, and the effect that lower reimbursement rates would have on our tenants' and borrowers' business; the risk that the cash flows of our tenants and borrowers would be adversely affected by increased liability claims and liability insurance costs; risks related to environmental laws and the costs associated with liabilities related to hazardous substances; the risk that we may not be fully indemnified by our lessees and borrowers against future litigation; the success of our future acquisitions and investments; our ability to reinvest cash in real estate investments in a timely manner and on acceptable terms; the potential need to incur more debt in the future, which may not be available on terms acceptable to us; our ability to meet covenants related to our indebtedness which impose certain operational limitations and a breach of those covenants could materially adversely affect our financial condition and results of operations; the risk that the illiquidity of real estate investments could impede our ability to respond to adverse changes in the performance of our properties; risks associated with our investments in unconsolidated entities, including our lack of sole decision-making authority and our reliance on the financial condition of other interests; our dependence on revenues derived mainly from fixed rate investments in real estate assets, while a portion of our debt bears interest at variable rates; the risk that our assets may be subject to impairment charges; and our dependence on the ability to continue to qualify for taxation as a real estate investment trust. Many of these factors are beyond the control of the Company and its management. The Company assumes no obligation to update any of the foregoing or any other forward looking statements, except as required by law, and these statements speak only as of the date on which they are made. Investors are urged to carefully review and consider the various disclosures made by NHI in its periodic reports filed with the Securities and Exchange Commission, including the risk factors and other information disclosed in NHI's Annual Report on Form 10-K for the most recently ended fiscal year. Copies of these filings are available at no cost on the SEC's web site at http://www.sec.gov or on NHI's web site at https://www.nhireit.com.

Contact: John L. Spaid, Chief Financial Officer

Phone: (615) 890-9100

SOURCE: National Health Investors via EQS Newswire

ReleaseID: 576945

NHI Announces Increase in First Quarter 2020 Dividend

MURFREESBORO, TN / ACCESSWIRE / February 19, 2020 / National Health Investors, Inc. (NYSE:NHI) announced today that it will increase its quarterly dividend by 5.0% to $1.1025 per common share. Dividends are payable on May 8, 2020 to shareholders of record as of March 31, 2020.

This marks the 11th straight year that NHI has increased its quarterly dividend by 5% or more while maintaining a prudent payout ratio at or below 80% of normalized FFO in each of the last seven years.

About NHI

Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals. For more information, visit www.nhireit.com.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding the Company's, tenants', operators', borrowers' or managers' expected future financial position, results of operations, cash flows, funds from operations, dividend and dividend plans, financing opportunities and plans, capital market transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, acquisition integration, growth opportunities, expected lease income, continued qualification as a real estate investment trust ("REIT"), plans and objectives of management for future operations, continued performance improvements, ability to service and refinance our debt obligations, ability to finance growth opportunities, and similar statements including, without limitation, those containing words such as "may," "will," "believes," "anticipates," "expects," "intends," "estimates," "plans," and other similar expressions are forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Such risks and uncertainties include, among other things, the operating success of our tenants and borrowers for collection of our lease and interest income; the success of property development and construction activities, which may fail to achieve the operating results we expect; the risk that our tenants and borrowers may become subject to bankruptcy or insolvency proceedings; risks related to governmental regulations and payors, principally Medicare and Medicaid, and the effect that lower reimbursement rates would have on our tenants' and borrowers' business; the risk that the cash flows of our tenants and borrowers would be adversely affected by increased liability claims and liability insurance costs; risks related to environmental laws and the costs associated with liabilities related to hazardous substances; the risk that we may not be fully indemnified by our lessees and borrowers against future litigation; the success of our future acquisitions and investments; our ability to reinvest cash in real estate investments in a timely manner and on acceptable terms; the potential need to incur more debt in the future, which may not be available on terms acceptable to us; our ability to meet covenants related to our indebtedness which impose certain operational limitations and a breach of those covenants could materially adversely affect our financial condition and results of operations; the risk that the illiquidity of real estate investments could impede our ability to respond to adverse changes in the performance of our properties; risks associated with our investments in unconsolidated entities, including our lack of sole decision-making authority and our reliance on the financial condition of other interests; our dependence on revenues derived mainly from fixed rate investments in real estate assets, while a portion of our debt bears interest at variable rates; the risk that our assets may be subject to impairment charges; and our dependence on the ability to continue to qualify for taxation as a real estate investment trust. Many of these factors are beyond the control of the Company and its management. The Company assumes no obligation to update any of the foregoing or any other forward looking statements, except as required by law, and these statements speak only as of the date on which they are made. Investors are urged to carefully review and consider the various disclosures made by NHI in its periodic reports filed with the Securities and Exchange Commission, including the risk factors and other information disclosed in NHI's Annual Report on Form 10-K for the most recently ended fiscal year. Copies of these filings are available at no cost on the SEC's web site at https://www.sec.gov or on NHI's web site at https://www.nhireit.com.

Contact:

Dana Hambly
Director, Investor Relations
Phone: (615) 890-9100

SOURCE: National Health Investors, Inc. via EQS Newswire

ReleaseID: 576930

Gentherm, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 19, 2020 / Gentherm, Inc. (NASDAQ:THRM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 19, 2020 at 8:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/58304

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 576878